PerpEquities

Equity · Healthcare

Is Abbott Laboratories (ABT) tradable as a perp? Not yet

Abbott Laboratories is a global healthcare company developing and selling pharmaceuticals, diagnostics, nutritional products, and medical devices.

Not yet listed on any perp exchange

No perpetual-futures venue lists ABT yet. We track it continuously; as soon as the first listing appears, this page becomes a full market page. Until then: fundamentals below and tradable alternatives.

Similar stocks already tradable as perps
GILDNVOPFEAMGNVRTXISRG

Price chart

Interactive TradingView chart

TradingView symbol NYSE:ABT

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Company data

Company fundamentals

Updated 5h ago
Market cap
$187.4B
Updated 5h ago
Revenue
$46.6B
Trailing 12 months
Revenue growth
+13%
Next fiscal year
Profit margin
+11.6%
P/E
34.8
Peer P/E 23.4
Free cash flow
$8.7B
Trailing 12 months
More metrics
Net income
$5.4B
Trailing 12 months
P/S
4.0
Peer P/E
23.4
Similar listed perps
Revenue estimate
$50.3B
Next fiscal year
Earnings
2026-10-21
Revenue est. $13B · Updated 5h ago
Dividend
$0.63
2026-07-15

Fundamental detail

Annual + quarterly
Latest revenue$44.3B
Net margin+14.7%
Free cash flow$7.4B
Net debt$6.5B
2020$34.6B
2021$43.1B
2022$43.7B
2023$40.1B
2024$42B
2025$44.3B
PeriodRevenueGrowthNet incomeFCF
2020$34.6B+8%$4.5B$5.7B
2021$43.1B+24%$7.1B$8.6B
2022$43.7B+1%$6.9B$7.8B
2023$40.1B-8%$5.7B$5.1B
2024$42B+5%$13.4B$6.4B
2025$44.3B+6%$6.5B$7.4B
PeriodGross marginOperating marginNet marginROEROA
2020+50.2%+15.3%+13.0%+13.7%+6.2%
2021+53.9%+21.4%+16.4%+19.8%+9.4%
2022+51.1%+19.2%+15.9%+18.9%+9.3%
2023+50.0%+16.0%+14.3%+14.8%+7.8%
2024+50.8%+16.3%+31.9%+28.1%+16.5%
2025+55.5%+18.2%+14.7%+12.5%+7.5%
PeriodCashDebtNet debtCurrent ratio
2020$6.8B$19.9B$13.1B1.72
2021$9.8B$19.3B$9.5B1.85
2022$9.9B$17.9B$8.1B1.63
2023$6.9B$15.9B$9B1.64
2024$7.6B$15.3B$7.7B1.67
2025$8.5B$15.1B$6.5B1.58
PeriodMarket capEnterprise valueP/SP/E
2020$194.1B$207.2B5.643.4
2021$249.8B$259.3B5.835.5
2022$192.5B$200.5B4.427.9
2023$190.9B$199.8B4.833.4
2024$195.9B$203.5B4.714.7
2025$218.9B$225.4B4.933.5
Q3 2024$10.6B
Q4 2024$11B
Q1 2025$10.4B
Q2 2025$11.1B
Q3 2025$11.4B
Q4 2025$11.5B
Q1 2026$11.2B
Q2 2026$12.6B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$10.6B+5%$1.6B$2.1B
Q4 2024$11B+7%$9.2B$2.1B
Q1 2025$10.4B+4%$1.3B$933M
Q2 2025$11.1B+7%$1.8B$1.5B
Q3 2025$11.4B+7%$1.6B$2.3B
Q4 2025$11.5B+4%$1.8B$2.6B
Q1 2026$11.2B+8%$1.1B$916M
Q2 2026$12.6B+13%$928M$2.9B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+51.0%+17.1%+15.5%+4.1%+2.2%
Q4 2024+51.0%+18.1%+84.1%+19.4%+11.3%
Q1 2025+52.6%+16.3%+12.8%+2.7%+1.6%
Q2 2025+56.4%+18.4%+16.0%+3.5%+2.1%
Q3 2025+55.7%+18.1%+14.5%+3.2%+2.0%
Q4 2025+57.0%+19.6%+15.5%+3.4%+2.0%
Q1 2026+56.3%+16.5%+9.6%+2.1%+1.0%
Q2 2026+58.0%+14.2%+7.4%+1.8%+0.8%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$7.6B$15B$7.4B1.60
Q4 2024$7.6B$15.3B$7.7B1.67
Q1 2025$6.5B$13.2B$6.7B1.78
Q2 2025$7B$13.4B$6.5B1.82
Q3 2025$7.5B$12.9B$5.4B1.70
Q4 2025$8.5B$15.1B$6.5B1.58
Q1 2026$6.8B$34B$27.2B1.39
Q2 2026$5.1B$32.6B$27.5B1.38
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$197.7B$205.2B18.630.0
Q4 2024$195.9B$203.5B17.85.3
Q1 2025$231.8B$238.5B22.443.7
Q2 2025$236.7B$243.2B21.233.3
Q3 2025$234.3B$239.7B20.635.6
Q4 2025$218.9B$225.4B19.130.7
Q1 2026$179.4B$206.6B16.141.4
Q2 2026$158.2B$185.7B12.642.8
Historical value series
Revenue
Q3 2023: $10.1BQ4 2023: $10.2BQ1 2024: $10BQ2 2024: $10.4BQ3 2024: $10.6BQ4 2024: $11BQ1 2025: $10.4BQ2 2025: $11.1BQ3 2025: $11.4BQ4 2025: $11.5BQ1 2026: $11.2BQ2 2026: $12.6BQ3 2023Q2 2026
Net income
Q3 2023: $1.4BQ4 2023: $1.6BQ1 2024: $1.2BQ2 2024: $1.3BQ3 2024: $1.6BQ4 2024: $9.2BQ1 2025: $1.3BQ2 2025: $1.8BQ3 2025: $1.6BQ4 2025: $1.8BQ1 2026: $1.1BQ2 2026: $928MQ3 2023Q2 2026
EBITDA
Q3 2023: $2.6BQ4 2023: $2.8BQ1 2024: $2.4BQ2 2024: $2.6BQ3 2024: $2.9BQ4 2024: $3BQ1 2025: $2.7BQ2 2025: $3BQ3 2025: $3.1BQ4 2025: $2.8BQ1 2026: $2.2BQ2 2026: $1.8BQ3 2023Q2 2026
Free cash flow
Q3 2023: $1.3BQ4 2023: $2.3BQ1 2024: $627MQ2 2024: $1.4BQ3 2024: $2.1BQ4 2024: $2.1BQ1 2025: $933MQ2 2025: $1.5BQ3 2025: $2.3BQ4 2025: $2.6BQ1 2026: $916MQ2 2026: $2.9BQ3 2023Q2 2026
EPS
Q3 2023: $0.82Q4 2023: $0.91Q1 2024: $0.7Q2 2024: $0.74Q3 2024: $0.94Q4 2024: $5.27Q1 2025: $0.76Q2 2025: $1.01Q3 2025: $0.94Q4 2025: $1.02Q1 2026: $0.62Q2 2026: $0.53Q3 2023Q2 2026
Cash / Debt
Q3 2023 · Cash: $6.7BQ3 2023 · Debt: $15.5BQ4 2023 · Cash: $6.9BQ4 2023 · Debt: $15.9BQ1 2024 · Cash: $6.3BQ1 2024 · Debt: $14.6BQ2 2024 · Cash: $7BQ2 2024 · Debt: $14.8BQ3 2024 · Cash: $7.6BQ3 2024 · Debt: $15BQ4 2024 · Cash: $7.6BQ4 2024 · Debt: $15.3BQ1 2025 · Cash: $6.5BQ1 2025 · Debt: $13.2BQ2 2025 · Cash: $7BQ2 2025 · Debt: $13.4BQ3 2025 · Cash: $7.5BQ3 2025 · Debt: $12.9BQ4 2025 · Cash: $8.5BQ4 2025 · Debt: $15.1BQ1 2026 · Cash: $6.8BQ1 2026 · Debt: $34BQ2 2026 · Cash: $5.1BQ2 2026 · Debt: $32.6BQ3 2023Q2 2026
CashDebt
Profitability
Q3 2023 · Gross margin: +49.6%Q4 2023 · Gross margin: +51.3%Q1 2024 · Gross margin: +50.4%Q2 2024 · Gross margin: +51.1%Q3 2024 · Gross margin: +51.0%Q4 2024 · Gross margin: +51.0%Q1 2025 · Gross margin: +52.6%Q2 2025 · Gross margin: +56.4%Q3 2025 · Gross margin: +55.7%Q4 2025 · Gross margin: +57.0%Q1 2026 · Gross margin: +56.3%Q2 2026 · Gross margin: +58.0%Q3 2023 · Operating margin: +16.5%Q4 2023 · Operating margin: +18.2%Q1 2024 · Operating margin: +13.9%Q2 2024 · Operating margin: +16.2%Q3 2024 · Operating margin: +17.1%Q4 2024 · Operating margin: +18.1%Q1 2025 · Operating margin: +16.3%Q2 2025 · Operating margin: +18.4%Q3 2025 · Operating margin: +18.1%Q4 2025 · Operating margin: +19.6%Q1 2026 · Operating margin: +16.5%Q2 2026 · Operating margin: +14.2%Q3 2023 · Net margin: +14.2%Q4 2023 · Net margin: +15.6%Q1 2024 · Net margin: +12.3%Q2 2024 · Net margin: +12.5%Q3 2024 · Net margin: +15.5%Q4 2024 · Net margin: +84.1%Q1 2025 · Net margin: +12.8%Q2 2025 · Net margin: +16.0%Q3 2025 · Net margin: +14.5%Q4 2025 · Net margin: +15.5%Q1 2026 · Net margin: +9.6%Q2 2026 · Net margin: +7.4%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth
Q3 2024: +4.9%Q4 2024: +7.2%Q1 2025: +4.0%Q2 2025: +7.4%Q3 2025: +6.9%Q4 2025: +4.4%Q1 2026: +7.8%Q2 2026: +13.0%Q3 2023Q2 2026
Shares outstanding
Q3 2023: 1.7BQ4 2023: 1.7BQ1 2024: 1.8BQ2 2024: 1.8BQ3 2024: 1.7BQ4 2024: 1.7BQ1 2025: 1.7BQ2 2025: 1.8BQ3 2025: 1.7BQ4 2025: 1.7BQ1 2026: 1.7BQ2 2026: 1.7BQ3 2023Q2 2026
Valuation
Q3 2023 · P/E: 29.2Q4 2023 · P/E: 29.9Q1 2024 · P/E: 39.5Q2 2024 · P/E: 34.4Q3 2024 · P/E: 30.0Q4 2024 · P/E: 5.3Q1 2025 · P/E: 43.7Q2 2025 · P/E: 33.3Q3 2025 · P/E: 35.6Q4 2025 · P/E: 30.7Q1 2026 · P/E: 41.4Q2 2026 · P/E: 42.8Q3 2023 · P/S: 16.6Q4 2023 · P/S: 18.6Q1 2024 · P/S: 19.5Q2 2024 · P/S: 17.2Q3 2024 · P/S: 18.6Q4 2024 · P/S: 17.8Q1 2025 · P/S: 22.4Q2 2025 · P/S: 21.2Q3 2025 · P/S: 20.6Q4 2025 · P/S: 19.1Q1 2026 · P/S: 16.1Q2 2026 · P/S: 12.6Q3 2023Q2 2026
P/EP/S
Revenue
2018: $30.6B2019: $31.9B2020: $34.6B2021: $43.1B2022: $43.7B2023: $40.1B2024: $42B2025: $44.3B20182025
Net income
2018: $2.4B2019: $3.7B2020: $4.5B2021: $7.1B2022: $6.9B2023: $5.7B2024: $13.4B2025: $6.5B20182025
EBITDA
2018: $6.9B2019: $7.9B2020: $9B2021: $12.2B2022: $11.9B2023: $10.6B2024: $10.8B2025: $11.6B20182025
Free cash flow
2018: $4.9B2019: $4.5B2020: $5.7B2021: $8.6B2022: $7.8B2023: $5.1B2024: $6.4B2025: $7.4B20182025
EPS
2018: $1.342019: $2.062020: $2.52021: $3.942022: $3.912023: $3.272024: $7.642025: $3.7220182025
Cash / Debt
2018 · Cash: $3.8B2018 · Debt: $19.6B2019 · Cash: $3.9B2019 · Debt: $19.1B2020 · Cash: $6.8B2020 · Debt: $19.9B2021 · Cash: $9.8B2021 · Debt: $19.3B2022 · Cash: $9.9B2022 · Debt: $17.9B2023 · Cash: $6.9B2023 · Debt: $15.9B2024 · Cash: $7.6B2024 · Debt: $15.3B2025 · Cash: $8.5B2025 · Debt: $15.1B20182025
CashDebt
Profitability
2018 · Gross margin: +51.7%2019 · Gross margin: +52.3%2020 · Gross margin: +50.2%2021 · Gross margin: +53.9%2022 · Gross margin: +51.1%2023 · Gross margin: +50.0%2024 · Gross margin: +50.8%2025 · Gross margin: +55.5%2018 · Operating margin: +12.6%2019 · Operating margin: +14.4%2020 · Operating margin: +15.3%2021 · Operating margin: +21.4%2022 · Operating margin: +19.2%2023 · Operating margin: +16.0%2024 · Operating margin: +16.3%2025 · Operating margin: +18.2%2018 · Net margin: +7.7%2019 · Net margin: +11.6%2020 · Net margin: +13.0%2021 · Net margin: +16.4%2022 · Net margin: +15.9%2023 · Net margin: +14.3%2024 · Net margin: +31.9%2025 · Net margin: +14.7%20182025
Gross marginOperating marginNet margin
Revenue growth
2019: +4.3%2020: +8.5%2021: +24.5%2022: +1.3%2023: -8.1%2024: +4.6%2025: +5.7%20182025
Shares outstanding
2018: 1.8B2019: 1.8B2020: 1.8B2021: 1.8B2022: 1.8B2023: 1.7B2024: 1.7B2025: 1.7B20182025
Valuation
2018 · P/E: 53.62019 · P/E: 42.02020 · P/E: 43.42021 · P/E: 35.52022 · P/E: 27.92023 · P/E: 33.42024 · P/E: 14.72025 · P/E: 33.52018 · P/S: 4.22019 · P/S: 4.82020 · P/S: 5.62021 · P/S: 5.82022 · P/S: 4.42023 · P/S: 4.82024 · P/S: 4.72025 · P/S: 4.920182025
P/EP/S

Refreshed 5h ago

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20265.52$50.3B+13%17
FY 20276.06$54.7B+23%17
FY 20286.72$58.5B+32%11
FY 20297.45$62.9B+42%4
FY 20308.28$67.2B+52%4
Q1 20271.28$12.8B+15%8

Company events

6
2026-10-21EarningsActual - / Estimate 1.43-
2026-07-16EarningsActual 1.31 / Estimate 1.28Beat
2026-07-15Dividend$0.63-
2026-04-16EarningsActual 1.15 / Estimate 1.14Beat
2026-04-15Dividend$0.63-
2026-01-22EarningsActual 1.5 / Estimate 1.5In line

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
GILD$187.5B6.2-58.1-10.6%7NVO$206.9B4.011.4+35.3%13PFE$162.1B2.537.6+6.8%3AMGN$236B6.227.0+22.9%7VRTX$138.6B11.031.5+34.9%3ISRG$129.5B11.741.4+28.4%8REGN$85.3B5.519.8+27.9%5BSX$71B3.419.3+17.5%2